COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
09/06/2026
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the [...]
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
09/06/2026
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment [...]
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
09/06/2026
Alison Strutt appointed as Chief Financial Officer, László Tank ó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executive Director Appointments support MitoRx’s next phase of growth as the [...]
Kraig Biocraft Laboratories Sets New All-Time Production Record, Delivering Nearly 2.5 Metric Tons of Recombinant Spider Silk in Single Production Cycle
09/06/2026
Company Continues Delivering on Aggressive 2026 Expansion Strategy as Production Scale Reaches New Heights ANN ARBOR, Mich., June 09, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the [...]
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
09/06/2026
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the [...]
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
09/06/2026
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial [...]
CVRx Announces Chief Financial Officer Transition
09/06/2026
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
09/06/2026
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% BURLINGTON, Mass. and JERUSALEM, June 09, 2026 (GLOBE [...]
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
09/06/2026
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham - Elraglusib will be assessed in [...]
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
09/06/2026
Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of [...]
Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
09/06/2026
ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your [...]
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
09/06/2026
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary [...]
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
09/06/2026
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED This FDA-aligned trial targets the specific [...]
AscellaHealth Establishes International Strategic Advisory Council, Enhances Global Life Sciences Support Services Amid Regulatory and Market Complexity
09/06/2026
DUBLIN and BERWYN, Pa., June 09, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the formation of its [...]
Philips Future Health Index 2026: AI is already saving clinicians time and delivering measurable impact in healthcare
09/06/2026
June 9, 2026 AI saves clinicians the equivalent of 16 working days a year, with half saying it has increased their capacity to see patients 39% say AI has identified or helped prevent potential medical errors at least [...]
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
09/06/2026
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED This FDA-aligned trial targets the specific [...]
Transactions in connection with share buy-back program
09/06/2026
Company announcement no. 20 - 26 9 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
FloBiotech Announces Agreement with UCLA Health® to Advance Neurodegenerative Disease Therapeutics
09/06/2026
BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- FloBiotech today announced an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in [...]
Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson's Disease Programme
09/06/2026
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease Two-year programme expands Harness' [...]

Pages